MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS

por Muldoon, Daniel, Zhao, Guisheng, Batt, Carly, Singh, Mallika, Nicolaides, Theodore
Publicado 2020

Lipoprotein particle alterations due to androgen therapy in individuals with dyskeratosis congenita

por Thompson, Mone't B., Muldoon, Daniel, de Andrade, Kelvin C., Giri, Neelam, Alter, Blanche P., Savage, Sharon A., Shamburek, Robert D., Khincha, Payal P.
Publicado 2021

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

por Thummalapalli, Rohit, Ricciuti, Biagio, Bandlamudi, Chaitanya, Muldoon, Daniel, Rizvi, Hira, Elkrief, Arielle, Luo, Jia, Alessi, Joao V., Pecci, Federica, Lamberti, Giuseppe, Di Federico, Alessandro, Hong, Lingzhi, Zhang, Jianjun, Heymach, John V., Gibbons, Don L., Plodkowski, Andrew J., Ravichandran, Vignesh, Donoghue, Mark T.A., Vanderbilt, Chad, Ladanyi, Marc, Rudin, Charles M., Kris, Mark G., Riely, Gregory J., Chaft, Jamie E., Hellmann, Matthew D., Vokes, Natalie I., Awad, Mark M., Schoenfeld, Adam J.
Publicado 2023